SAVE THE DATE:
You and your endocrinology and diabetes specialist colleagues are invited to
An ADA 2024 CME Expert Board Satellite Symposium on
Save the Date and Time – Register Now!
Friday, June 21, 2024
Registration: 6:30 PM
Dinner: 6:30 PM – 7:00 PM
CME Presentation: 7:00 PM – 8:30 PM
Location: Hyatt Regency Orlando
Ballroom: OPQ
For more information:
info@cmeducation.net
Program Agenda
6:30 PM – 6:40 PM
Chair’s Introduction
A Data-Driven Rationale for the Early Deployment of Continuous Glucose Monitoring (CGM)
Late-Breaking Trials and Guidance for Initial Interventions in Type 2 Diabetes
James R. Gavin, MD, PhD – Program Chair
Clinical Professor of Medicine
Emory University School of Medicine
Clinical Professor of Medicine
Indiana University School of Medicine
6:40 PM – 7:00 PM
Is CGM The Key to Managing Healthcare Utilization in Persons with Diabetes?
A Technology-Based Approach to Improving Outcomes and Reducing Hospitalization
Stewart B. Harris MD, MPH, FCFP, FACPM
Professor, Department of Family Medicine
Departments of Epidemiology and Biostatistics
Division of Endocrinology and Metabolism
Schulich School of Medicine & Dentistry
Western University
London, Ontario, Canada
7:00 PM – 7:20 PM
Moving Beyond HbA1c—Optimizing Time-in-Range for Persons with Type 2 Diabetes
Applying Advances in CGM for Improved Glycemic Management Before Insulin Initiation
Thomas W. Martens, MD
Medical Director
International Diabetes Center and Internal Medicine
Park Nicollet Clinic
Bloomington, MN
7:20 PM – 7:55 PM
Interactive Case-Based Clinic with CGM Experts’ Board: Data, Interventions, Patient Care Optimization
Early Application of CGM to Proactively Manage Type 2 Diabetes in the Real World
Eden Miller, DO
Founder
Diabetes and Obesity Care LLC
St. Charles Hospital
Bend, OR
Program Chair and Distinguished Faculty
James R. Gavin, MD, PhD
— Program Chair
Clinical Professor of Medicine
Emory University School of Medicine
Clinical Professor of Medicine
Indiana University School of Medicine
Stewart B. Harris MD, MPH, FCFP, FACPM
Professor, Department of Family Medicine
Departments of Epidemiology and Biostatistics
Division of Endocrinology and Metabolism
Schulich School of Medicine & Dentistry
Western University
London, Ontario, Canada
Thomas W. Martens, MD
Medical Director
International Diabetes Center and Internal Medicine
Park Nicollet Clinic
Bloomington, MN
Eden Miller, DO
Founder
Diabetes and Obesity Care LLC
St. Charles Hospital
Bend, OR
EDUCATIONAL AND LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
- Outline and discuss the evidentiary basis for sensor-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for persons with T2D and T1D within the diabetes and endocrinology specialty setting.
- Analyze the rationale and evidence for recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies.
- Compare and contrast available CGM-facilitating monitoring technologies and pair such technologies with optimal patient profiles.
- Educate persons with diabetes about the rationale, evidence, and outcome- optimizing results associated with technology-based, patient-centric and physician-directed CGM monitoring strategies that can be used to effect .optimal lifestyle, diet-, and pharmacology-based approaches to attaining guideline-based HA1c levels in persons with T2D and T1D.
- Identify which persons with diabetes are ideal candidates for a technology-based, patient-directed glucose monitoring system.
- Interpret and apply data and results from clinical trials in CGM-facilitating monitoring technologies to improve patient care, improve safety of drug therapy for T2D and T1D, detect and mitigate risk of hypoglycemia, improve patient- and physician-directed changes in antidiabetic therapy, reinforce the safe use of antidiabetic drugs, and facilitate patient-activated drug titration, glycemic monitoring and disease management.
- Translate landmark clinical studies focused on CGM-based technologies to the front lines of clinical practice in the diabetes and primary care; and understand the translational implications of deploying sensor-based CGM technologies as a foundational approach to improving outcomes in patients across the spectrum of diabetes.
TARGET AUDIENCE — WHO SHOULD ATTEND
This Clinical Excellence Summit is directed at the following: diabetes and endocrinology specialists and researchers and related healthcare providers who manage patients with Type 2 or Type 1 diabetes.
GRANTOR SUPPORT
Supported by an educational grant from Abbott Diabetes Care.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Chan Medical School and CMEducation Resources, LLC. The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The University of Massachusetts Chan Medical School designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
FACULTY & PROVIDER DISCLOSURE
It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
———